Subcutaneous administration of brain natriuretic peptide in experimental heart failure
Horng H. Chen, MB, BCh,
J. Aaron Grantham, MD,
John A. Schirger, MD,
Michihisa Jougasaki, MD, PhD,
Margaret M. Redfield, MD and
John C. Burnett, Jr., MD
View larger version (19K):
[in a new window]
|
Figure 1 Plasma BNP and plasma cGMP and UcGMPV excretion BL, 30, 60, 120, 180, 240 and 300 min after SQ BNP administration. Open bar = acute low-dose group; solid bar = acute high-dose group. *p < 0.05 vs. BL;  p < 0.05 vs. acute low-dose group. BL = baseline; BNP = brain natriuretic peptide; cGMP = 3',5'-cyclic guanosine monophosphate; SQ = subcutaneous; UcGMPV = urinary cGMP excretion.
|
|
View larger version (24K):
[in a new window]
|
Figure 2 Right atrial pressure, PCWP, UNaV, DFNaR at BL, 30, 60, 120, 180, 240 and 300 min after SQ BNP administration. *p < 0.05 vs. BL. BL = baseline; DFNaR = distal fractional reabsorption of sodium; PCWP = pulmonary capillary wedge pressure; RAP = right atrial pressure; SQ = subcutaneously; UNaV = urine sodium excretion.
|
|
View larger version (16K):
[in a new window]
|
Figure 3 Cardiac output, PCWP and SVR of the dogs in the chronic BNP group (treated HF) on day 11 or rapid ventricular pacing compared with dogs with untreated HF on day 11 of rapid ventricular pacing. *p < 0.05 vs. untreated HF. BNP = brain natriuretic peptide; CO = cardiac output; HF = heart failure; PCWP = pulmonary capillary wedge pressure; SVR = systemic vascular resistance.
|
|
|
